Biomarker for Arteriovenous Fistula Dialysis Access Failure
Application
Plasma biomarker for the prediction of arteriovenous fistula (AVF) dialysis access failure during hemodialysis.
Key Benefits
- Circulating chymase levels predict AVF failure in chronic hemodialysis patients.
- Proprietary antibody while other proprietary antibodies do not work as biomarkers.
- The ability to predict AVF failure may help providers select an alternate dialysis modality or initial vascular access type.
Market Summary
Approximately half of the AVF's surgically created never mature sufficiently to sustain chronic hemodialysis and ultimately fail, primarily due to the development of intimal hyperplasia (IH). Currently, no biomarker is available to predict the likelihood of AVF failure. This technology offers a clinical approach to predict AVF failure through the measurement of serum chymase.
Technical Summary
Emory researchers have shown that chymase expression is abnormally elevated in patients with chronic kidney disease, that it is expressed in veins with IH, and that elevated serum chymase level is predictive of AVF failure. Dialysis is primarily used to provide an artificial replacement for lost kidney function in patients with kidney failure. Patients have different dialysis options and the most common type of dialysis in the United States is hemodialysis. Vascular access, which provides repeated, reliable access to the bloodstream, is required for hemodialysis. The optimal form of hemodialysis vascular access is the AVF, a conduit surgically created in the arm connecting an artery and a vein, which takes several weeks to properly mature for hemodialysis.
Developmental Stage
Human clinical studies have demonstrated a significant increase in chymase levels in AVF non-maturation patients.
Patent Information
| App Type |
Country |
Serial No. |
Patent No. |
File Date |
Issued Date |
Patent Status |
| Nationalized PCT - United States |
United States |
14/127,206 |
9,724,412 |
12/18/2013 |
8/8/2017 |
Issued |
|
|